Feedback
Settings

Settings

Goto Application

1. WO2020131807 - INHIBITORS OF APOL1 AND METHODS OF USING SAME

PermaLink
Publication Number WO/2020/131807
Publication Date 25.06.2020
International Application No. PCT/US2019/066746
International Filing Date 17.12.2019
IPC
A61P 13/12 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
C07D 403/12 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
A61K 31/4025 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4025not condensed and containing further heterocyclic rings, e.g. cromakalim
CPC
A61K 31/404
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403condensed with carbocyclic rings, e.g. carbazole
404Indoles, e.g. pindolol
A61K 31/675
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
675having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/69
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
69Boron compounds
A61K 31/695
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
695Silicon compounds
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
C07B 2200/05
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
2200Indexing scheme relating to specific properties of organic compounds
05Isotopically modified compounds, e.g. labelled
Applicants
  • VERTEX PHARMACEUTICALS INCORPORATED [US]/[US]
Inventors
  • BRODNEY, Michael
  • GAGNON, Kevin
  • HU, Kan-Nian
  • MEDEK, Ales
  • ROSE, Peter
  • SHI, Yi
  • SHRESTHA, Muna
  • WITKOS, Faith
  • CAO, Jingrong
  • COME, Jon H.
  • DAKIN, Leslie A.
  • DENIS, Francois
  • DORSCH, Warren A.
  • FORTIER, Anne
  • HAMEL, Martine
  • KRUEGER, Elaine B.
  • LEDFORD, Brian
  • NANTHAKUMAR, Suganthini S.
  • NICOLAS, Olivier
  • SAYEGH, Camil
  • SENTER, Timothy J.
  • WANG, Tiansheng
Agents
  • MACALPINE, Jill K.
Priority Data
62/780,66717.12.2018US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) INHIBITORS OF APOL1 AND METHODS OF USING SAME
(FR) INHIBITEURS D'APOL1 ET LEURS PROCÉDÉS D'UTILISATION
Abstract
(EN) The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
(FR) L'invention concerne au moins une entité choisie parmi des composés de formule (I), des formes à l'état solide de ceux-ci, des compositions les comprenant, et des procédés d'utilisation de ceux-ci, comprenant l'utilisation dans le traitement de la glomérulosclérose segmentaire focale (FSGS) et/ou d'une maladie rénale non diabétique (NDKD).
Related patent documents
UY0001038514
US20200377479
AU2019405477
AR116913
SG11202105769X
BR112021011564
KR1020210116483
CN113453760
CR20210383
EP3897833
PE2021-2302
JP2022515369
EA202191710
IL283592
CA3121910
NZ776979
DOP2021000116
CL2021001561
DODOP2021000116This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
MXMX/a/2021/007152This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
NI2021-000049 IThis application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
DJDJ/B/2021/0004This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
AEP6001011/2021This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
IN202117028947
CO20210009053
CRCR2021-000383This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
ECSP21052184
UAa202104153This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
SA521422270This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau
# -